Myosin Heavy Chain 9: Oncogene or Tumor Suppressor Gene?
نویسندگان
چکیده
منابع مشابه
AMPK: a contextual oncogene or tumor suppressor?
The AMP-activated protein kinase (AMPK) functions to monitor and maintain energy homeostasis at the cellular and organism level. AMPK was perceived historically primarily as a component of the LKB1/STK11 tumor suppressor (LKB1 mutations cause the Peutz-Jegher cancer predisposition syndrome) cascade upstream of the TSC1/2/mTOR pathway and thus likely to be a tumor suppressor. However, AMPK has r...
متن کاملRhoB: Team Oncogene or Team Tumor Suppressor?
Although Rho GTPases RhoA, RhoB, and RhoC share more than 85% amino acid sequence identity, they play very distinct roles in tumor progression. RhoA and RhoC have been suggested in many studies to contribute positively to tumor development, but the role of RhoB in cancer remains elusive. RhoB contains a unique C-terminal region that undergoes specific post-translational modifications affecting ...
متن کاملCoexpression of Myosin Heavy Chain 2b with Myosin Heavy Chain 1- Fact or Artefact
In skeletal muscle, pure fibres expressing one myosin heavy chain (MyHC) isoform, and intermediate fibres, expressing two and exceptionally three MyHCs have been described. When skeletal muscle adapts its fibre type profile to changed functional demands MyHC isoform transformation follows the pathway: MyHC-1 ↔ MyHC-2a ↔ MyHC-2x/d ↔ MyHC-2b. Therefore, in hybrid fibres only successive isoforms f...
متن کاملIs miR-29 an oncogene or tumor suppressor in CLL?
B-cell chronic lymphocytic leukemia (CLL), the most common leukemia in the Western world. CLL occurs in two forms, aggressive and indolent. Aggressive CLL is characterized by high ZAP-70 expression and unmutated IgH V(H); indolent CLL shows low ZAP-70 expression and mutated IgH V(H). We recently found that miR-29 is up-regulated in indolent human B-CLL, compared to aggressive B-CLL and normal C...
متن کاملIGF-Binding Protein 2 – Oncogene or Tumor Suppressor?
The role of insulin-like growth factor binding protein 2 (IGFBP2) in cancer is unclear. In general, IGFBP2 is considered to be oncogenic and its expression is often observed to be elevated in cancer. However, there are a number of conflicting reports in vitro and in vivo where IGFBP2 acts in a tumor suppressor manner. In this mini-review, we discuss the factors influencing the variation in IGFB...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Medical Science Monitor
سال: 2019
ISSN: 1643-3750
DOI: 10.12659/msm.912320